Navigation Links
YM BioSciences licensee Pulmokine awarded NIH funding to develop small molecule drugs for pulmonary hypertension
Date:9/29/2010

ytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia which are currently being evaluated.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; that and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 New interactive ... innovative thought leaders of the medical device industry ... conference and expo, from June 18-20 in ... http://photos.prnewswire.com/prnh/20130517/613829 ) , These ... industry professionals practical presentations and implementable solutions on ...
(Date:5/17/2013)... SAN JOSE, Calif. , May 17, 2013 ... an agreement has been reached with ... entire portfolio of anti-infective human monoclonal antibody (mAb) ... six anti-infective human mAb products for treatment of ... strains of Staphylococcus aureus , Pseudomonas ...
(Date:5/17/2013)... 17, 2013 The paradigm of ‘one ... systems that can help predict the adverse and therapeutic ... Stepaniants, Head of Computational Biology at the Genomics Laboratory, ... to ensure high-quality genomics when used as part of ... to complex data sets to identify key clinical targets ...
(Date:5/17/2013)... IAC Industries wants to share with you the ... to set up and furnish a research lab knowing that ... a year’s time. How does a company make choices in ... What is efficient and cost-effective? , The solution was ... The planners at DisperSol determined that the concept of modular ...
Breaking Biology Technology:MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2
... STAAR Surgical Company,(Nasdaq: STAA ) today ... quarter and full year ended January 2, 2009 on ... The Company will host a conference call and webcast,on ... 1:30 p.m. Pacific to discuss,the Company,s fourth quarter and ...
... PARIS, March 4 , 2008 Key milestones, - ... programs:, - Recruitment of 311 samples achieved ... EHT 0202 in Alzheimer,s disease, - Expansion of the strategic collaboration ... 2008 Key events, - Appointment of a new Management Board, ...
... Berkeley, CA - As electronic circuits shrink from ... elusive proportions, researchers at the U.S. Department of ... Columbia University are studying how electrons flow through ... contacts gold atoms with a single molecule. Their ...
Cached Biology Technology:STAAR Surgical Announces Fourth Quarter and Full Year 2008 Earnings Release Date and Conference Call 2ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 2ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 3ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 4ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 5ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 6ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 7ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 8ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 9ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 10ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 11Researchers discover a potential on-off switch for nanoelectronics 2Researchers discover a potential on-off switch for nanoelectronics 3Researchers discover a potential on-off switch for nanoelectronics 4
(Date:5/17/2013)... A new Dartmouth College study finds human-caused climate ... of tropical lizards, contradicting a host of recent ... rapidly warming planet. , The findings, which appear ... offer new hope for survival of a creature ... Most predictions that tropical cold-blooded animals, especially forest ...
(Date:5/16/2013)... Illustrating a commitment to the support of ... (AGA) Research Foundation has announced the inaugural AGA ... recipients. Supported by the National Institute of Diabetes ... award helps underrepresented minority students to further their ... , "By establishing this new award, AGA demonstrates ...
(Date:5/16/2013)... closer to a fast food restaurant had a higher ... away from fast food, according to researchers at The ... association was particularly strong among those with a lower ... the American Journal of Public Health indicates ... food restaurant, and among lower-income African-Americans, the density, or ...
Breaking Biology News(10 mins):Climate change may have little impact on tropical lizards 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3
... that abnormal stimulation of a cellular trigger that ... causes invasive tumor-like growths in mice. Removing the ... the researchers said suggests a possible treatment for ... , Arturo Alvarez-Buylla and Erica L. Jackson, of ...
... that years after experiencing childhood polio, most survivors ... their elderly counterparts, but rather experience only modest ... aging. , "Other researchers have suggested that polio ... but we've actually found it to be relatively ...
... A pioneering collaboration among U.S., European and Australian researchers ... differences in the way people respond to HIV. , ... University, investigators who once competed to unravel the mysteries ... cohorts, they have studied. , Support for the consortium ...
Cached Biology News:Possible birthplace of malignant brain tumors identified 2Survivors of childhood polio do well decades later as they age 2CHAVI announces international search for genes affecting HIV response 2CHAVI announces international search for genes affecting HIV response 3
... This microscope is described by end-users to ... incorporates the fundamentals of light microscopy and ... small footprint, it does not require much ... a busy lab environment. The DM-BA300 combines ...
... ergonomic microscopes are now available in digital ... DM-BA200 comes packed with Motic's patented Colour ... plug and play digital image capture head. ... a reversed quadruple nosepiece, deliver high quality ...
This kit is designed to select cells labeled with biotinylated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
... system combines the space and time dimensions of ... the optical microscope to open new horizons in ... source for excitation, the decay of a fluorescence ... the decay measured. Subtle changes in the ...
Biology Products: